26.20
+2.54%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arcutis Biotherapeutics
From its filings with the US Securities and Exchange Commission
Arcutis Biotherapeutics is based in Westlake Village, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ARQT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $376.1m and a net loss of $16.1m. At that date it held total assets of $433.0m and shareholders' equity of $189.5m.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization. Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to address the major shortcomings of existing therapies in our targeted indications. We believe this strategy uniquely positions us to rapidly advance our goal of bridging the treatment innovation gap in dermatology, while maximizing our probability of technical success and financial resources.
We launched our lead product, ZORYVE cream 0.3%, in August 2022 after obtaining our initial FDA approval for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas (e.g. groin or axillae), in individuals 12 years of age or older. ZORYVE cream 0.3% is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. ZORYVE cream 0.3% is approved for once-daily topical treatment of mild, moderate, and severe plaque psoriasis with no limitations on location or duration of use.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 Jan 2020
- Employees
- 354
- Website
- arcutis.com ↗
- Head office
- 3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA, 91361
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Patrick HeronIndependent Chairman of the Board$336,984
- Mr. Todd WatanabePresident, Chief Executive Officer, Director, since 2016$3.7m
- Ms. Latha VairavanChief Financial Officer, Senior Vice President
- Dr. Patrick BurnettExecutive Vice President, Chief Medical Officer$2.5m
- Mr. L. Todd EdwardsExecutive Vice President, Chief Commercial Officer$2.0m
- Mr. Masaru MatsudaSenior Vice President, General Counsel$1.7m
- Dr. Bhaskar ChaudhuriIndependent Director$315,000
- Ms. Terrie CurranIndependent Director$310,000
- Ms. Halley GilbertIndependent Director$310,000
- Ms. Neha KrishnamohanIndependent Director$310,000
- Mr. Keith LeonardIndependent Director$313,016
- Ms. Sue-Jean LinIndependent Director$325,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 39
- Environment
- 23
- Social
- 48
- Governance
- 45
- Women in the workforce
- 59%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arcutis Biotherapeutics Inc has several strengths that contribute to its success in the market. Firstly, the company has a robust and experienced research and development team composed of top-notch scientists and experts in the field of dermatology. This allows them to develop innovative and effective biotherapeutics for various skin conditions.
- In addition, Arcutis Biotherapeutics Inc has established strong partnerships with key players in the pharmaceutical industry. These collaborations provide the company with access to additional resources, expertise, and distribution channels, enabling them to reach a wider audience and accelerate the commercialization of their products.
- Furthermore, the company has a diverse and promising pipeline of potential treatments for a range of dermatological diseases. This helps mitigate the risks associated with relying on a single product and enhances their potential for long-term growth and revenue generation.
Weaknesses
- Despite its strengths, Arcutis Biotherapeutics Inc faces certain weaknesses that could hinder its performance. One primary weakness is its heavy reliance on external collaborations for product development and commercialization. While partnerships can bring advantages, it also introduces additional complexities and dependency on external entities, potentially slowing down decision-making processes and compromising the company's control over its products.
- Another weakness lies in the fact that Arcutis Biotherapeutics Inc is a relatively young company compared to some of its competitors. This may result in limited brand recognition and market penetration, making it challenging to establish a strong foothold in the highly competitive dermatology sector.
Opportunities
- Arcutis Biotherapeutics Inc operates in a favorable market environment with increasing demand for effective dermatological treatments. This presents opportunities for the company to capitalize on market growth and expand its product portfolio to cater to unmet medical needs.
- Additionally, advancements in technology and research offer new possibilities for the development of innovative therapies. By leveraging these opportunities, Arcutis Biotherapeutics Inc can maintain a competitive edge and differentiate itself from competitors.
Threats
- Like any other company, Arcutis Biotherapeutics Inc faces threats in its operating environment. One significant threat is the presence of well-established competitors with strong brand recognition and extensive market presence. This increases the challenge for Arcutis Biotherapeutics Inc to attract and retain customers in a crowded market.
- Additionally, regulatory and compliance requirements in the pharmaceutical industry pose a threat to the company's operations. Changes in regulations or failure to comply with existing regulations could result in delays in product approvals or even the withdrawal of approved products from the market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.